Fredun Pharmaceuticals Limited

Transaction Details

  • Total Equity Shares Allotted: 44,000 equity shares of face value ₹10 each
  • Warrants Converted: 14,667 convertible warrants
  • Allotment Date: October 23, 2026
  • Shareholder Approval Date: October 22, 2025 (Extra-Ordinary General Meeting)
  • Original Warrant Allotment Date: December 29, 2025

Allottee Details

| Name | Category | Original Warrants Allotted | Equity Shares Allotted | Outstanding Warrants | Post-Bonus Effect |

| Divya Aggarwal | Non-Promoter | 8,000 | 2,667 | 0 | 8,000 |

| Indu Ramanlal Golecha | Non-Promoter | 8,000 | 8,000 | 0 | 24,000 |

| Sahil Dhir | Non-Promoter | 4,000 | 4,000 | 0 | 12,000 |

| Total | | 20,000 | 14,667 | 0 | 44,000 |

Bonus Issue Impact

The Company's 1:2 bonus issue proportionately adjusted warrant entitlements, resulting in:

  • Each warrant now convertible to three equity shares (instead of the original ratio)
  • Exercise price revised accordingly
  • Total 44,000 shares allotted instead of the original 14,667 warrant conversion entitlement

Financial Terms

  • Original Warrant Issue Price: ₹1,250 per warrant
  • Upfront Payment: ₹312.50 per warrant (25% of issue price)
  • Balance Consideration: Paid in full before conversion
  • Security Type: Fully paid-up equity shares

Additional Information

  • Allotment made in dematerialized form
  • New shares rank pari passu with existing equity shares
  • Board meeting duration: 3:00 PM to 5:45 PM (October 23, 2026)
  • No cancellation or termination of the issuance proposal